Researchers at the Institute of Science Tokyo developed an mRNA vaccine that, when administered intramuscularly, effectively suppresses pathological retinal neovascularization in mouse models of wet age-related macular degeneration (AMD). The vaccine encodes leucine-rich alpha-2-glycoprotein 1 (LRG1), an angiogenesis-promoting protein elevated in AMD patients. Unlike conventional anti-VEGF treatments requiring direct ocular injections, this approach offers a non-invasive alternative with potential for improved patient compliance and sustained efficacy against neovascular eye diseases.